According to the International Neuroblastoma Risk Group (INRG) classification scheme, NB is classified as low, medium and high risk based on MYCN amplification status, metastasis, and whether the patient is older than 18 months (Monclair et al., 2009). This evidence concerns the gene MYCN and neuroblastoma.